他克莫司治疗膜性肾病Meta分析.pdf

20 1 2011 2 # 23# M eta : M eta(MN) : Cochrane ubM ed, M edline database ( CNK I)( VI ) MN ( random ized controlled clin ical trials, RCT), 2010 9 25, M eta : 5, 188M eta , , MN( RR= 216 95% , CI 132~ 355) ( RR = 159 95% , CI 127~ 201), : , MN FK506 M eta Tacrolimus in treatment of membranous nephropathy byMeta analysis ZHAN G J ie,H E X u, ZHAN G L iw en, X U M in, LI J ing, LI U Guangling D ep ar tm ent of Pediatr ic, J ing ling H o p ital, N anj ing Un iver ity School of M edicine, N anj ing 210002, China Correp onding author: LIU Guang ling (Email: liu. g uang ling@ 163. com ) ABSTRACT Objective: To assess the effect and safety of tacrolmi us in treatm ent of membranous nephropathy by M eta analysis. M ethodology: The data of Cochrane L ibrary, ubM ed, CNK I and V I until September 25, 2010 w ere retrieved to search the studies about the random ized controlled clinical trials ( RCTs) in the treatm ent of m em branous nephropathy by tacrolmi us. Standard stud iesw ere used by quality evaluation and M eta analysis. The qualities of included articles were assessed and then a metaanalysis was conducted. Results: Five RCTs stud ies in w hich included 188 patients at hom e and abroad w ere collected. M eta analysis show ed that compared w ith the control group, tacrolmi usw as m ore effective in com plete rem issions (RR= 21695% , CI 132~ 355) and totalrem ission (RR= 159 95% , CI 127~ 201). Adverse effect could be recovered by symptomatic treatm ent. Conclusion:The current lmi ited evidence suggests that tacrolmi us ism ore effective than traditional protocols in treatment ofm em bra